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ABSTRACT
Background: High-risk human papillomaviruses (HPV) cause most anal, vaginal, vulvar, penile, and
oropharyngeal cancers, and virtually all cervical cancers. In 2014, in Georgia (GA), fewer than half of adolescent
females and males aged 13-17 years received the three doses of the HPV vaccine. Increasing vaccination coverage
among this age group, education of adolescents in regard to HPV risks, and cervical cancer screening of adults
can prevent HPV-associated cancers.
Methods: The incidence of HPV-associated cancers for 2008-2012 in GA was obtained from GA Comprehensive
Cancer Registry data. Case definitions for HPV-associated cancers were based on standard definitions of the
Centers for Disease Control and Prevention (CDC). Data for anatomic sites known to have HPV-associated
cancers, including the cervix, vulva, vagina, penis, anus, and oropharynx, were analyzed. Also derived were ageadjusted rates, age-specific incidence rates, the percentage of each cancer found attributable to HPV, and ageadjusted incidence rates by geography.
Results: During 2008-2012, a total of 6,056 HPV-associated cancers were diagnosed (males, 2,408; females,
3,648). Of these, 4,629 cancers were attributable to HPV (males, 1,574; females, 3,055). The most common
cancers attributable to HPV were oropharyngeal cancers among males (1,182); and cervical cancers (1,862)
among females. Females living in smaller urban counties had a higher cervical cancer incidence rate than females
living in metropolitan counties and metro areas (1 million or more population). Males living in rural counties had
a lower oropharyngeal cancer incidence compared to the state incidence rate.
Conclusions: Since HPV vaccination at age 11-12 years can prevent HPV-related cancers in adulthood, clinicians
should promote HPV vaccination along with routine immunizations to adolescents. Surveillance of HPVassociated cancers using GA cancer registry data is needed to track future changes in incidence data due to
administering the HPV vaccine, increasing cervical cancer screening, and educating youth in GA about HPV risk
factors.
Keywords: human papillomavirus; HPV-associated cancers; HPV vaccination; Georgia; adolescents
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Immunization
Practices
recommends
routine
vaccination of females aged 11-12 years with 3 doses
of Cervarix®, Gardasil®, or Gardasil 9® and routine
vaccination of males aged 11-12 years with 3 doses of
Gardasil® or Gardasil 9®. Vaccination is also
recommended for females aged 13 through 26 years
and males aged 13 through 21 years who have not
been vaccinated previously or who did not complete 3
doses of the vaccine (Petrosky et al., 2015).

INTRODUCTION
Human papillomavirus (HPV) is a group of related
viruses that cause warts on the arms, chest, hands feet,
and mucous membranes. Genital HPV occurs on the
mucous membranes, which are the moist surface
layers of the body that are open to the outside, such as
the vagina, anus, mouth, and throat. High-risk HPV
types have been linked with and are known to cause
cancer (American Cancer Society, 2015). High-risk or
oncogenic human papillomaviruses cause most anal,
vaginal, vulvar, penile, oropharyngeal cancers, and
virtually all cervical cancers. Most HPV infections
clear without treatment within 1 to 2 years, but
infections that persist for many years can progress to
pre-cancers or cancers (National Cancer Institute
[NCI]), 2015). The Advisory Committee on
http://www.gapha.org/jgpha/

Cervarix® (bivalent) prevents infection with HPV
types 16 and 18; Gardasil® (quadrivalent) prevents
infection with types 6, 11, 16, and 18; and Gardasil
9® (9-valent) prevents infection with types 6, 11, 16,
18, 31, 33, 45, 52, and 58, all of which cause anal,
vulvar, vaginal and cervical pre-cancers and cancers.
Either of the three vaccines can be used to prevent
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infection with HPV types 16 and 18, which are
responsible for 70% of cervical cancers and cause
about half of vaginal, vulvar, and penile cancers (NCI,
2015). Further, these vaccines prevent formation of
anal, vulvar, vaginal, and cervical pre-cancers and
cancers caused by HPV-16 and HPV-18.

Program, Chronic Disease, Healthy Behaviors and
Injury Epidemiology Section of the Georgia
Comprehensive Cancer Registry Unit (GCCR). Case
definitions for HPV-associated cancers were based on
CDC’s Morbidity and Mortality Weekly Report
(MMWR)
http://www.cdc.gov/mmwr/preview/mmwrhtml/mm61
15a2.htm:
“Human
Papillomavirus-Associated
Cancers – United States, 2004-2008,” in order to
analyze the burden of invasive cancers at specific
anatomic sites known to be associated with HPV,
including cancers of the cervix, vulva, vagina, penis,
anus, and oropharynx. Additionally, included in the
analyses were specific cell types known to contain
HPV DNA; these were carcinoma of the cervix and
squamous cell carcinoma (scc) for all other sites
(Centers for Disease Control and Prevention, 2012).
For oropharyngeal cancers specific sites included
were those where HPV was most likely to be found:
base of the tongue, tonsils, and other sites in the
oropharynx. Age-adjusted rates and age-specific
incidence rates were calculated per 100,000 persons
using Statistical Analysis Software (SAS®) 9.4 and
standardized to the 2000 U.S. Standard Population.
Incidence rates were considered significant at p≤0.05.
Based on previous reports, the percentage of each
cancer found attributable to HPV was calculated by
multiplying the average annual number of HPVassociated cancers by the percentage of cancers
attributable to HPV (Gillson et al., 2008). Data were
analyzed by sex, age, race/ethnicity, and geographic
location. Race/ethnicity categories included nonHispanic (NH) whites and NH blacks. The incidence
of HPV-associated cancers by geography was
calculated by use of 2013 Rural-Urban Continuum
Codes used to classify metropolitan (metro) counties
by the population size of their metro area and
nonmetropolitan counties by degree of urbanization
and adjacency to a metro area or areas.
Metro>1million includes counties in metro areas of 1
million population or more (N=29). Metro 250,000-1
million includes counties in metro areas of 250,000 to
1 million population (N=15). Metro<250,000 includes
counties in metro areas of fewer than 250,000
population (N=30). Smaller Urban includes urban
population of 20,000 or more, adjacent to a metro
area, Urban population of 20,000 or more, not
adjacent to a metro area, Urban population of 2,500 to
19,999, adjacent to a metro area, and Urban
population of 2,500 to 19,999, not adjacent to a metro
area (N=63). Rural includes completely rural or less
than 2,500 urban population, adjacent to a metro area,
and completely rural or less than 2,500 urban
population, not adjacent to a metro area (N=22).
Figure 1 shows the Metro, Metro Adjacent, and Rural
Counties classification for GA.

Other HPV types, such as HPV 31, 33, 45, 52, and 58,
cause about 25% of cervical pre-cancers and 10% of
invasive HPV-associated cancers. HPV types 6 and 11
cause 90% of anogential warts and most cases of
recurrent respiratory papillomatosis (Petrosky et al.,
2015). Further, HPV-16, which causes about 85% of
all cases of anal cancer, has been linked to more than
half of the cancers diagnosed in the oropharynx (NCI,
2015). HPV vaccines, which protect against high-risk
HPV types known to cause cancer, are most effective
when given before an adolescent becomes sexually
active. HPV transmission can also be reduced by
screening for cervical cancer, using condoms, and
limiting the number of sexual partners (American
Cancer Society, 2015). Cervical cancer screening with
a Papanicolaou (Pap) test can help find abnormal
tissues or precancerous lesions at an early stage,
which are treatable (NCI, n.d.). In the United States,
cervical cancer screening guidelines recommend
screening women ≥21 years old every 3 years with the
Pap test alone and women ≥30 years every 5 years
with a Pap test and an HPV DNA test (NCI, n.d.).
The Centers for Disease and Control and Prevention
(CDC) analyzed 2004-2008 data from the National
Program of Cancer Registries (NPCR), the NCI, and
Surveillance, Epidemiology, and End Results (SEER)
program to determine the incidence of HPVassociated cancers in the United States, including all
50 states and the District of Columbia. During this
timeframe, approximately 33,369 HPV-associated
cancers were diagnosed annually in the United States- 12,080 among males and 21,290 among females.
The national analysis showed that approximately
26,000 new cancers were attributable to HPV (18,000
among females and 8,000 among males) (Human
Papillomavirus-Associated Cancers – U.S., 2012).
The objective of the present research was to determine
the incidence of HPV-associated cancers in Georgia
(GA) by analyzing cancer registry data for GA from
2008-2012, provide estimates on the HPV-associated
cancers, and examine the incidence of HPVassociated cancers by geography.
METHODS
The incidence of HPV-associated cancers in GA
during 2008-2012 were calculated from data obtained
from the Georgia Department of Public Health,
Division of Health Protection, Epidemiology

http://www.gapha.org/jgpha/
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Figure 1. Metro, metro adjacent, and rural counties, Georgia, 2013

Data Sources: Georgia Department of Public Health, Division of Health Protection, Epidemiology Program, Chronic Disease,
Healthy Behaviors and Injury Epidemiology Section, Georgia Comprehensive Cancer Registry (2008-2012)
Updated: January 2016
Visit: http://dph.georgia.gov/georgia-comprehensive-cancer-registry for more information about cancer in Georgia.

http://www.gapha.org/jgpha/
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Table 1. HPV-associated cancers*, by anatomic site, age group, sex, and race/ethnicity Georgia, 2008-2012
Oropharyngeal SCC
Female
Male
Rate per
Total
Total
Rate per
100,000
number
100,000
Characteristic
(95% CI) number
(95% CI)
Total
Age (yrs)
0-19
20-29
30-39
40-49
50-59
60-69
70-79
≥80
Race/Ethnicity
Non-Hispanic Black
Non-Hispanic White

1876

7.8

(7.5, 8.2)

447

1.7

(1.5, 1.8)

0
32
253
694
613
228
54

0.0
1.0
7.0
8.3
30.5
23.1
12.8

(0.0, 0.0)
(0.7, 1.3)
(6.2, 7.9)
(7.3, 9.3)
(28.1, 32.9)
(20.1, 26.1)
(9.3, 16.2)

0
54
137
136
79
27

0.0
1.5
4.2
6.0
6.4
3.4

(0.0, 0.0)
(1.1, 1.8)
(3.5, 4.9)
(5.0, 7.0)
(5.0, 7.8)
(2.1, 4.6)

343
1493

6.1

(5.4, 6.8)
(8.6, 9.5)

96
340

1.3

(1.0, 1.5)
(1.7, 2.1)

9.0



AAR=1.9/100,000)
than
NH
blacks
(males:
AAR=6.1/100,000; females: AAR=1.3/100,000). Anal
cancer
was
higher
among
females
(AAR=2.2/100,000) than males (AAR=1.6/100,000)
and was significantly higher among NH white females
(AAR=2.6/100,000) compared to NH black females
(AAR=1.5/100,000). However, anal cancer was
higher (but not statistically different) among NH black
males (AAR=1.9/100,000) compared to NH white
males (AAR=1.5/100,000) (Table 1).

RESULTS
During 2008-2012, 6,056 HPV-associated cancers
were diagnosed in GA-- 2,408 among males and 3,648
among females. For males, oropharyngeal cancer was
the most common, with 1,876 cases annually (Table
1). Males (age-adjusted rate (AAR) =7.8/100,000)
were more than four times more likely to be
diagnosed with oropharyngeal cancer than females
(AAR=1.7/100,000). For both sexes, oropharyngeal
cancer was significantly higher among NH whites
(males:
AAR=9.0/100,000;
females:

http://www.gapha.org/jgpha/
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Total
number

Anal SCC
Male
Rate per
100,000
(95% CI)

Total
number

Female
Rate per
100,000

(95% CI)

Total
Age (yrs)
0-19
20-29
30-39
40-49
50-59
60-69
70-79
≥80
Race/Ethnicity
Non-Hispanic Black

353

1.6

(1.4, 1.7)

599

2.2

(2.1, 2.4)

0
30
112
97
63
31
18

0
0.9
3.2
1.1
3.2
3.3
4.3

(0.0,0.0)
(0.6, 1.2)
(2.6, 3.7)
(0.7, 1.4)
(2.4, 4.0)
(2.1, 4.5)
(2.3, 6.2)

0
0
92
312
200
114
78

0
0
2.5
6.5
6.1
6.7
7.3

(0.0,0.0)
(0.0,0.0)
(2.0, 3.0)
(5.7, 7.4)
(5.0, 7.1)
(5.3, 8.2)
(5.5, 9.2)

119

1.9

(1.6, 2.3)

109

1.5

Non-Hispanic White

222

1.5

(1.3, 1.7)

467

2.6



(1.2, 1.8)
(2.4, 2.9)

 Significant
Data Sources: Georgia Department of Public Health, Division of Health Protection, Epidemiology
Program, Chronic Disease, Healthy Behaviors and Injury Epidemiology Section, Georgia
Comprehensive Cancer Registry (2008-2012)
Updated: January 2016

Penile cancer rates were higher, but not significant,
among NH black males (AAR= 1.1/100,000)
compared to NH white males (AAR= 0.8/100,000).
Cervical cancer, with 1,940 cases, was the most
common cancer among females (Table 1). The rate of
cervical cancer was higher among NH black females
than NH white females (AAR=8.8 /100,000 vs AAR=
7.7/100,000). Rates of vulvar cancer were

http://www.gapha.org/jgpha/

significantly higher among NH white females
(AAR=2.5/100,000) than NH
black females
(AAR=1.5/100,000). Vaginal cancer rates were
slightly
higher
among
NH
black
females
(AAR=0.7/100,000) compared to NH white females
(AAR=0.4/100,000).
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Total
number

Characteristic
Total
Age (yrs)
0-19
20-29
30-39
40-49
50-59
60-69
70-79
≥80
Race/Ethnicity
Non-Hispanic Black
Non-Hispanic White

ISSN 2471-9773

Penile SCC
Rate per
100,000
(95% CI)

Cervical Carcinoma
Total
Rate per
number
100,000
(95% CI)

Total
number

Vulva SCC
Rate per
100,000
(95% CI)

Total
number

Vaginal SCC
Rate per
100,000
(95% CI)

179

0.9

(0.7, 1.0)

1940

7.7

(7.4, 8.1)

537

2.1

(1.9, 2.3)

125

0.5

(0.4, 0.6)

0
0
_
25
32
52
44
19

0
0
_
0.7
1.1
2.6
4.7
4.5

(0.0,0.0)
(0.0,0.0)
_
(0.4, 1.0)
(0.7, 1.4)
(1.9, 3.4)
(3.3, 6.0)
(2.4, 6.5)

_
105
446
500
406
255
127
96

_
3.0
13.0
13.8
12.5
11.3
10.3
11.8

_
(2.5, 3.6)
(11.8, 14.2)
(12.6, 15.1)
(11.2, 13.7)
(9.9, 12.7)
(8.5, 12.1)
(9.5, 14.2)

0
_
29
93
103
123
103
83

0
_
0.9
2.5
3.2
5.4
8.4
10.3

(0.0,0.0)
_
(0.5, 1.2)
(2.0, 3.0)
(2.6, 3.8)
(4.5, 6.4)
(6.8, 10.0)
(8.1, 12.5)

0
0
_
_
215
137
83
60

0
0
_
_
0.8
1.6
1.8
3.1

(0.0,0.0)
(0.0,0.0)
_
_
(0.5, 1.0)
(1.1, 2.2)
(1.0, 2.5)
(1.9, 4.3)

46
123

1.1
0.8

(0.7, 1.4)
(0.7, 1.0)

639
1118

8.8
7.7

(8.1, 9.5)
(7.2, 8.1)

101
414

1.5

(1.2, 1.8)
(2.2, 2.7)

47
72

0.7
0.4

(0.5, 0.9)
(0.3, 0.5)

2.5



*HPV-associated cancers are defined as cancers at specific anatomic sites and with specific cellular types in which HPV DNA frequently is
found. Data are from the Georgia Cancer Registry. Only carcinomas are included for cervical cancer. Only SCCs are included for vulvar, vaginal,
penile, anal, and oropharyngeal cancers. Anal cancers include SCCs coded to the rectum. All cell types (histology) were microscopically
confirmed. Oropharyngeal sites and other definitions specified in: Centers for Disease Control and Prevention (2012). Oropharyngeal sites and
other definitions specified in: Centers for Disease Control and Prevention (2012). CDC definitions were based on Watson, (2008).
 Significant

¶Data suppressed because the total number of cancers for 2008-2012 was <16.

Data Sources: Georgia Department of Public Health, Division of Health Protection, Epidemiology Program, Georgia Comprehensive Cancer
Registry (2008-2012)
Updated: January 2016
Visit: http://dph.georgia.gov/georgia-comprehensive-cancer-registry for more information about cancer in Georgia.

http://www.gapha.org/jgpha/
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In GA, 4,629 cancers that occurred during 2008-2012
were attributable to HPV -- 1,574 among males and
3,055 among females. The most common cancers
attributable to HPV were oropharyngeal cancers
(1,182) among males and cervical cancers (1,862)
among females (Table 2).

compared to the state incidence rate; males living in
rural counties had a significantly lower rate. Males
living in smaller urban counties had the lowest anal
SCC incidence rate. Males living in smaller urban
counties had the highest penile SCC incidence rate
and males living in metro counties (1 million or more)
had the lowest rate.

Males living in metro counties (250,000 to 1 million)
had the highest oropharyngeal incidence rate
Table 2. Estimated percentages and numbers of cancers attributable to human HPV by anatomic site and sex,
Georgia, 2008-2012
Site

Oropharynx
Male
Female
Anus
Male
Female
Penis
Cervix
Vulva
Vagina

Total number

% attributable to HPV*

Number attributable to HPV**

%

Range

Total number

5 Yrs Annual
Average

1876
447

63
63

(50-75)
(50-75)

1182
282

236
56

353
599
179
1940
537
125

93
93
36
96
51
64

(86-97)
(86-97)
(26-47)
(95-97)
(37-65)
(43-82)

328
557
64
1862
274
80

66
111
13
372
55
16

*Source: Gillison et al., 2008.
**The estimated number of HPV-attributable cancers calculated by multiplying the HPV-associated cancer counts from Table 1
by the percentage of each cancer attributable to HPV. Estimates were rounded to the nearest tenth or hundredth. Female and male
anal cancers do not equal the total number of anal cancers because of rounding.

Table 3. Age-adjusted incidence rates (2008-2012) by geography, Georgia
Oropharyngeal SCC
Anal SCC
Male
Female
Male
Female
Rate per
Rate per
Rate per
Rate per
Group
95% CI
95% CI
95% CI
95% CI
100,000
100,000
100,000
100,000
Metro 1M+
7.6
(7.1, 8.1)
1.6
(1.4, 1.8)
1.6
(1.4, 1.9)
2.1
(1.8, 2.3)
Metro 250K-1M
9.0
(7.9, 10.1)
2.0
(1.5, 2.5)
1.7
(1.2, 2.2)
2.2
(1.7, 2.8)
Metro <250K
8.6
(7.7, 9.6)
1.7
(1.3, 2.1)
1.5
(1.1, 1.9)
2.6
(2.1, 3.1)
Smaller urban
7.7
(6.8, 8.5)
1.9
(1.5, 2.3)
1.3
(0.9, 1.6)
2.3
(1.8, 2.7)
1.8
(1.0, 2.7)
2.9
(1.8, 4.0)
Rural
5.7
(4.1, 7.3)

Females living in metro counties (250,000 to
1 million) had the highest oropharyngeal incidence
rate, and females living in metro counties (1 million or
more) had the lowest rate. Females living in rural
counties had the highest anal SCC incidence rate, and
females living in metro counties (1 million or more)
had the lowest rate. Females living in smaller urban
counties had a significantly higher cervical cancer
incidence rate than females living in metro counties
(1 million or more) and females living in metro

http://www.gapha.org/jgpha/

counties (1 million or more) had the lowest rate.
Females living in smaller urban counties had the
highest vulvar SCC incidence rate, and females living
in metro counties (less than 250,000) had the lowest
rate. Females living in metro counties (250,000 to
1 million) had the highest vaginal SCC incidence rate.
Females living in all geographical areas in GA had
similar rates of vaginal cancer (Table 3).
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Penile SCC
Group

Rate per
100,000

0.8
0.9
0.8
1.2
-

Metro 1M+
Metro 250K-1M
Metro <250K
Smaller urban
Rural

ISSN 2471-9773

Cervical Carcinoma

95% CI

Rate per
100,000

(0.6, 1.0)
(0.5, 1.3)
(0.5, 1.1)
(0.9, 1.6)
-

7.0
8.8
8.5
8.9
8.5

Vulvar SCC

95% CI

Rate per
100,000

(6.6, 7.5)
(7.7,9.9)
(7.6, 9.5)
(8.0, 9.9)
(6.1, 10.8)

1.8
2.7
1.7
2.8
2.7

Vaginal SCC

95% CI

Rate per
100,000

95% CI

(1.6, 2.1)
(2.1, 3.2)
(1.3, 2.1)
(2.3, 3.3)
(1.6, 3.9)

0.5
0.6
0.5
0.5
-

(0.3, 0.6)
(0.3, 0.9)
(0.3, 0.8)
(0.3, 0.7)
-

 Significant

The 2013 Rural-Urban Continuum was used to classify metropolitan (metro) counties by the population size of their
metro area, nonmetropolitan counties by degree of urbanization and adjacency to a metro area or areas.
Metro>1million includes counties in metro areas of 1 million population or more.
Metro 250,000-1million includes counties in metro areas of 250,000 to 1 million population.
Metro<250,000 includes counties in metro areas of fewer than 250,000 population.
Smaller Urban includes urban population of 20,000 or more, adjacent to a metro area; Urban population of 20,000 or
more, not adjacent to a metro area; Urban population of 2,500 to 19,999, adjacent to a metro area; and Urban population
of 2,500 to 19,999, not adjacent to a metro area.
Rural includes completely rural or less than 2,500 urban population, adjacent to a metro area, and completely rural or less
than 2,500 urban population, not adjacent to a metro area.

According to the National Immunization SurveyTeen, in 2014, in GA 65.4% of females and 41.2% of
males aged 13-17 years received ≥1 dose of HPV
vaccine, but only 47.1% of females and 21.0% of
males aged 13-17 years received ≥3 doses. Nationally,
60.0% of females and 41.7% of males aged 13-17
years received ≥1 dose of HPV vaccine, but only
39.7% of females and 21.6% of males aged 13-17
years received ≥3 doses (Georgia Department of
Public Health, 2015). Thus, few adolescents
completed the recommended 3 doses of the HPV
vaccine. Estimates of HPV vaccine uptake for females
in GA were higher than national estimates. GA HPV
vaccination estimates among males were similar to
national estimates at ≥1 and ≥3 doses, but lower than
estimates among GA females, indicating the need for
increased promotion of the HPV vaccine among males
(Georgia Department of Public Health, 2015).
Increasing vaccination coverage among this age group
is necessary to protect adolescents from HPV
exposure. Further, improving cervical cancer
screening should prevent the development of invasive
cervical cancer. Among some parents with at least one
child between ages 10 to 15 years old, there is a lack
of understanding of the HPV vaccine (Olshen et al.,
2005). Acceptability is higher among parents who
believe their child, at some point, would be exposed to
HPV. Parents disagree on the age to vaccinate; some
believed it would be easier to vaccinate at a younger
age; some worry about encouraging unsafe sexual
activity; and others want their child to take part in the
decision to be vaccinated. Physician recommendation
affects parental acceptance of vaccination. Similarities
were found in a systematic review of HPV vaccine
acceptability. As established in this review, parents
had positive reactions to the HPV vaccine and were
comfortable with it when they believed that the
vaccine was effective, a physician recommended the
vaccine, and they felt HPV infection was likely
(Brewer et al., 2007).

DISCUSSION
In GA, incidence rates were calculated for specific
sites known to be associated with HPV. The vulvar
scc incidence rate for GA was higher than the U.S.
rate (2.1/100,000 vs. 1.8/100,000). For GA, the
incidence rates for vulvar, anal, and oropharyngeal scc
among males and females were higher than U.S. rates.
Vaginal and penile cancer incidence rates were
slightly higher than those for the U.S., while cervical
cancer incidence rates in GA were similar to the U.S.
(Human Papillomavirus-Associated Cancers – U.S.,
2012). In GA from 2008-2012, females had a higher
total number of cases than males (females, 3,648;
males, 2,408) from 2008-2012. Slightly more than
half of the total cases among females in GA were due
to cervical cancer (1,940, 53.2%). Of 2,408 cases
among males, more than half were from
oropharyngeal cancer (1,876, 77.9%).
According to the Behavioral Risk Factor Surveillance
Survey in 2014, the cervical cancer screening rate for
women aged 21-65, using 2012 screening guidelines,
was 89% in GA overall, 88% among NH white
females, and 95% among NH black females. Although
cervical cancer screening rates were higher among
NH black females, from 2008-2012 the age-adjusted
cervical cancer incidence for this group was the
highest in the state (9.2 per 100,000) (Georgia
Comprehensive Cancer Registry, 2015). High cervical
cancer screening rates could indicate a targeted effort
in reaching and screening this population and may
indicate a reduced access to screening services among
this group and/or to a lack of follow up (Shavers &
Brown, 2002; Fiscella et al., 2011). HPV vaccination
should help reduce cervical cancer incidence rates.
Barriers, including a lack of understanding of the
HPV vaccine and age to vaccinate, along with strong
physician recommendation must be addressed (Olshen
et al., 2005; Brewer et al., 2007; Gilkey et al., 2015).
http://www.gapha.org/jgpha/
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Provider education is needed so that HPV vaccination
among adolescents can coincide with routine
immunizations.
Physician
reluctance
to
recommending the HPV vaccine suggests a lack of
assurance, understanding, and approach in which to
discuss the vaccine with parents. Providing HPV
vaccine communication strategies for healthcare
providers can enable them to utilize opportunities to
present the HPV vaccine to parents when discussing
the adolescent immunization schedule (Gilkey et al.,
2015).

The uptake of the HPV vaccine is reliant on physician
recommendations. When making health decisions for
their adolescents, parents generally trust what their
health providers recommend. In a study performed in
2014 (Gilkey et al., 2015), 776 U.S. physicians (53%
pediatricians, 47% family medicine physicians) were
surveyed. The study assessed perceptions and
communication in administering vaccines to 11-12
year old patients. Of the physicians, 73% reported that
the HPV recommendation was highly important for
adolescents, but only 13% viewed the HPV vaccine as
being highly important to parents. Physicians also
noted that the explanation for HPV vaccination took
twice as long as that for Tdap.

Additionally, among parents of adolescents there is a
lack of understanding about the nature of HPV and the
HPV vaccine. Educational campaigns should aim to
increase parents’ knowledge of HPV, the HPV
vaccine, and the importance of completing the HPV
vaccine dosage series before their teen engages in
sexual activity (Brewer et al., 2007). HPV planning
activities must address these barriers so that the
vaccine is recommended with the routine adolescent
immunization schedule and is promoted as a safe
procedure that prevents HPV infections and HPVassociated cancers. Further, there should be a
continued effort to promote cervical cancer screening,
especially to minority groups where disparities
remain. Since there are no screening programs for
oropharyngeal, anal, penile, vulvar, and vaginal HPVassociated cancers, HPV vaccination can be an
effective tool in the prevention of these cancers.

News media coverage of the HPV vaccine has
affected the uptake of HPV vaccination. One study
(Casciotti et al., 2014) found that news media
coverage of HPV vaccination often presented HPV
infection as unavoidable, used scare tactics, and
presented cervical cancer as life threatening, which
created fear. Additionally, 30% of articles presented
the ideas that HPV vaccination promotes premarital
sex and encourages sexual behavior. These issues
affected the perceptions, feelings, and attitudes
associated with HPV vaccination.
The differing incidence rates for HPV-associated
vulvar, vaginal, penile, and anal are not fully
understood. Differences may be due to demographics,
access to screening, tobacco use, or other
environmental or specific factors relating to HPV.
Differences in the incidence rate of oropharyngeal
cancers may be due to tobacco use and alcohol use.
HPV infection may also be involved. Differing risk
factors, such as age and sexual behaviors may also be
responsible for the varying incidence rates (Smith
et al., 2010). Geographically, no apparent trend was
seen as related to the Rural-Urban classification.

In 2014, the Georgia Cancer Registry met the highest
national data quality for cancer registry from the
CDC, NPCR, the National Cancer Institute, SEER,
and the North American Association of Central
Cancer Registries, Inc. (NAACCR) (North American
Association of Central Cancer Registries, Inc. [NAACCR],
2016); (National Program of Cancer Registries [NPCR],
2015). However, registry data do not capture HPV

status. Estimates are provided in this report, but the
number of HPV associated cancers and HPVattributable cancers may have been under- or overestimated. Smoking, demographics, and behavioral
factors may also be involved in the variation in rates
of HPV-associated cancers; these factors are not
captured in cancer registry data.

CONCLUSIONS
HPV-associated cancers can be prevented by HPV
vaccines, cervical cancer screening, and educating
youth about risk factors associated with HPV
infection. Surveillance of HPV-associated cancers
using GA cancer registry data is needed to track future
changes in incidence data due to administering the
HPV vaccine, recommending cervical cancer
screening, and educating youth in regard to risk
factors. Increasing vaccination coverage among young
adults will protect adolescents from HPV-related
infections. Parents of adolescents take physician
recommendations into consideration when making
health decisions. However physician’s reluctance in
recommending the HPV vaccine creates a missed
opportunity for parents to consider HPV vaccination
for their adolescent (Olshen et al., 2005; Brewer et al.,
2007; Gilkey et al., 2015).

http://www.gapha.org/jgpha/
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